08:00 , Feb 4, 2013 |  BC Week In Review  |  Company News

AvidBiologics, National Research Council (NRC) Canada deal

AvidBiologics partnered with the NRC to jointly develop three antibody-drug conjugates (ADC) against undisclosed targets to treat cancer. The antibodies were generated as part of the NRC's integrated therapeutic antibody development (ITAD) initiative. AvidBiologics said...